# Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer

> **NCT00437359** · PHASE2 · TERMINATED · sponsor: **Japan Breast Cancer Research Network** · enrollment: 240 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Toremifene citrate
- **DRUG:** Anastrozole

## Key facts

- **NCT ID:** NCT00437359
- **Lead sponsor:** Japan Breast Cancer Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2017-05
- **Final completion:** 2020-05
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2012-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00437359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00437359, "Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00437359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*